Recombinant Vaccine Delivery Vehicle: A Promising Tool to Treat Infections and Combat Antimicrobial Resistance

Overview

Journal Antibiotics (Basel)

Specialty Pharmacology

Date 2022 Dec 23

PMID 36551358

Authors

Yakhya Dieye

Cheikh Momar Nguer

Fatou Thiam

Abou Abdallah Malick Diouara

Cheikh Fall

Affiliations

Soon will be listed here.

Abstract

Antimicrobial resistance (AMR) has become a global public health threat. Experts agree that unless proper actions are taken, the number of deaths due to AMR will increase. Many strategies are being pursued to tackle AMR, one of the most important being the development of efficient vaccines. Similar to other bacterial pathogens, AMR in Helicobacter pylori (Hp) is rising worldwide. Hp infects half of the human population and its prevalence ranges from <10% in developed countries to up to 90% in low-income countries. Currently, there is no vaccine available for Hp. This review provides a brief summary of the use of antibiotic-based treatment for Hp infection and its related AMR problems together with a brief description of the status of vaccine development for Hp. It is mainly dedicated to genetic tools and strategies that can be used to develop an oral recombinant Hp vaccine delivery platform that is (i) completely attenuated, (ii) can survive, synthesize in situ and deliver antigens, DNA vaccines, and adjuvants to antigen-presenting cells at the gastric mucosa, and (iii) possibly activate desired compartments of the gut-associated mucosal immune system. Recombinant Hp vaccine delivery vehicles can be used for therapeutic or prophylactic vaccination for Hp and other microbial pathogens.

Citing Articles

Vaccines for cancer prevention: exploring opportunities and navigating challenges.

Graciotti M, Kandalaft L Nat Rev Drug Discov. 2024; 24(2):134-150.

PMID: 39622986 DOI: 10.1038/s41573-024-01081-5.

Epidemiology of Resistance to Antibiotics (A Narrative Review).

Mladenova I Antibiotics (Basel). 2023; 12(7).

PMID: 37508280 PMC: 10376713. DOI: 10.3390/antibiotics12071184.

References

Levit R, Cortes-Perez N, de Moreno de LeBlanc A, Loiseau J, Aucouturier A, Langella P . Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health. Gut Microbes. 2022; 14(1):2110821. PMC: 9377234. DOI: 10.1080/19490976.2022.2110821. View

Dieye Y, Hoekman A, Clier F, Juillard V, Boot H, Piard J . Ability of Lactococcus lactis to export viral capsid antigens: a crucial step for development of live vaccines. Appl Environ Microbiol. 2003; 69(12):7281-8. PMC: 309906. DOI: 10.1128/AEM.69.12.7281-7288.2003. View

Kennemann L, Didelot X, Aebischer T, Kuhn S, Drescher B, Droege M . Helicobacter pylori genome evolution during human infection. Proc Natl Acad Sci U S A. 2011; 108(12):5033-8. PMC: 3064335. DOI: 10.1073/pnas.1018444108. View

Aebischer T, Laforsch S, HURWITZ R, Brombacher F, Meyer T . Immunity against Helicobacter pylori: significance of interleukin-4 receptor alpha chain status and gender of infected mice. Infect Immun. 2000; 69(1):556-8. PMC: 97918. DOI: 10.1128/IAI.69.1.556-558.2001. View

Seyed N, Zahedifard F, Habibzadeh S, Yousefi R, Lajevardi M, Gholami E . Antibiotic-Free Nanoplasmids as Promising Alternatives for Conventional DNA Vectors. Vaccines (Basel). 2022; 10(10). PMC: 9611672. DOI: 10.3390/vaccines10101710. View

Axon A . Are all helicobacters equal? Mechanisms of gastroduodenal pathology and their clinical implications. Gut. 1999; 45 Suppl 1:I1-4. PMC: 1766659. DOI: 10.1136/gut.45.2008.i1. View

Fan E, ONeal C, Mitchell D, Robien M, Zhang Z, Pickens J . Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin. Int J Med Microbiol. 2004; 294(4):217-23. DOI: 10.1016/j.ijmm.2004.07.002. View

Humbert O, Salama N . The Helicobacter pylori HpyAXII restriction-modification system limits exogenous DNA uptake by targeting GTAC sites but shows asymmetric conservation of the DNA methyltransferase and restriction endonuclease components. Nucleic Acids Res. 2008; 36(21):6893-906. PMC: 2588503. DOI: 10.1093/nar/gkn718. View

Dailidiene D, Dailide G, Kersulyte D, Berg D . Contraselectable streptomycin susceptibility determinant for genetic manipulation and analysis of Helicobacter pylori. Appl Environ Microbiol. 2006; 72(9):5908-14. PMC: 1563642. DOI: 10.1128/AEM.01135-06. View

10.

Curtiss 3rd R, Xin W, Li Y, Kong W, Wanda S, Gunn B . New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol. 2010; 30(3):255-70. PMC: 3970581. DOI: 10.1615/critrevimmunol.v30.i3.30. View

11.

Malizia T, Tejada M, Marchetti F, Favini P, Pizzarelli G, Campa M . Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. J Antimicrob Chemother. 1998; 41 Suppl B:29-35. DOI: 10.1093/jac/41.suppl_2.29. View

12.

Khalifa M, Sharaf R, Aziz R . Helicobacter pylori: a poor man's gut pathogen?. Gut Pathog. 2010; 2(1):2. PMC: 2861632. DOI: 10.1186/1757-4749-2-2. View

13.

Sutton P, Boag J . Status of vaccine research and development for Helicobacter pylori. Vaccine. 2018; 37(50):7295-7299. PMC: 6892279. DOI: 10.1016/j.vaccine.2018.01.001. View

14.

Ierardi E, Losurdo G, Mileti A, Paolillo R, Giorgio F, Principi M . The Puzzle of Coccoid Forms of : Beyond Basic Science. Antibiotics (Basel). 2020; 9(6). PMC: 7345126. DOI: 10.3390/antibiotics9060293. View

15.

Scott D, Sachs G, Marcus E . The role of acid inhibition in eradication. F1000Res. 2018; 5. PMC: 4957631. DOI: 10.12688/f1000research.8598.1. View

16.

Ellermeier C, Janakiraman A, Slauch J . Construction of targeted single copy lac fusions using lambda Red and FLP-mediated site-specific recombination in bacteria. Gene. 2002; 290(1-2):153-61. DOI: 10.1016/s0378-1119(02)00551-6. View

17.

Debowski A, Carnoy C, Verbrugghe P, Nilsson H, Gauntlett J, Fulurija A . Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV. PLoS One. 2012; 7(4):e33310. PMC: 3325230. DOI: 10.1371/journal.pone.0033310. View

18.

Eletto D, Mentucci F, Voli A, Petrella A, Porta A, Tosco A . Pathogen-Associated Molecular Patterns: Friends or Foes?. Int J Mol Sci. 2022; 23(7). PMC: 8998707. DOI: 10.3390/ijms23073531. View

19.

Zhang R, Wang C, Cheng W, Duan G, Shi Q, Chen S . Delivery of Helicobacter pylori HpaA to gastrointestinal mucosal immune sites using Lactococcus lactis and its immune efficacy in mice. Biotechnol Lett. 2018; 40(3):585-590. DOI: 10.1007/s10529-017-2502-3. View

20.

Hajishengallis G, Nawar H, Tapping R, Russell M, Connell T . The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamers differentially induce and regulate cytokine production in human monocytic cells. Infect Immun. 2004; 72(11):6351-8. PMC: 523043. DOI: 10.1128/IAI.72.11.6351-6358.2004. View